Overview

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer

Status:
Not yet recruiting
Trial end date:
2024-08-10
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, exploratory clinical study
Phase:
Phase 2
Details
Lead Sponsor:
Hebei Medical University Fourth Hospital
Treatments:
Letrozole